Aptorum Stock Surges 115% on CLEP Test Approval Ahead of Merger

Aptorum Group Ltd. (APM) shares skyrocketed 115% in pre-market trading following regulatory approval for DiamiR Biosciences' APOE Genotyping test by New York State health authorities. The diagnostic breakthrough comes as both companies prepare for a merger slated to close in Q4 2025.

The NYSDOH-cleared test enables CLIA-certified analysis of blood, saliva, and tissue samples—a strategic advancement for neurodegenerative disease diagnostics. "This milestone accelerates our brain health portfolio," said DiamiR CEO Alidad Mireskandari, signaling potential in Alzheimer's research markets.

Thursday's rally erased Wednesday's 3.8% decline, demonstrating volatile investor sentiment around the biopharma's molecular testing ambitions. No cryptocurrency assets or digital exchanges were implicated in this equity movement.